Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 16/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057641 | 1.00 | P2RX3 (0.41) | P2RX3KDM4CMEN1KMT2ACNR2 | |
| SCHEMBL7051690 | 0.86 | P2RX3 (0.44) | P2RX3KDM4CMEN1KMT2ACNR2 | |
| SCHEMBL7060113 | 0.83 | MEN1 (0.44) | P2RX3KDM4CMEN1KMT2A | |
| SCHEMBL13563406 | 0.75 | NPC1 (0.39) | MEN1KMT2A | |
| SCHEMBL5777567 | 0.74 | KDM4E (0.46) | CNR2 | |
| SCHEMBL5774193 | 0.72 | PGR (0.43) | CNR2 | |
| SCHEMBL7059480 | 0.72 | TSHR (0.40) | — | |
| SCHEMBL7058025 | 0.71 | HPGD (0.62) | MEN1KMT2A | |
| SCHEMBL13563407 | 0.70 | ALDH1A1 (0.39) | MEN1KMT2ACNR2 | |
| SCHEMBL8195016 | 0.69 | MEN1 (0.46) | P2RX3KDM4CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322622-B1 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | SPROUT PHARMACEUTICALS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1322622-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6521623-B1 | 1-(2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl)-3-(2-hydroxyethyl) -1,3-dihydro-2H-benzimidazol-2-one for example; treating anxiety disorders and psychological disorders, brain injuries | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | Salix Pharmaceuticals, Ltd | 2003-02-06 | — | — | US | disclosed |
| WO-2002024661-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR3C | P2RX3 744/4885KDM4C 2238/4885MEN1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.